Case Study
Aptamers for Diagnostics
Case Study
Aptamers for Diagnostics
Detecting HIV through p24
Detecting HIV through the p24 protein in a diagnostic test is crucial due to its early appearance in the bloodstream during the acute phase of infection. p24 is a core protein found in the HIV virus. It is an essential structural component of the viral capsid, which surrounds and protects the viral genetic material. The p24 protein is released into the bloodstream during the early stages of HIV infection. By targeting p24, the test can detect HIV infection at an earlier stage when viral loads are high, enabling timely interventions, treatment initiation, and prevention of further transmission. This early detection plays a vital role in improving patient outcomes, reducing the spread of HIV, and facilitating effective public health strategies.
NeoVentures has developed aptamers specifically for targeting p24 for the purposes of creating a diagnostic test for HIV.
Detecting HIV through p24
Detecting HIV through the p24 protein in a diagnostic test is crucial due to its early appearance in the bloodstream during the acute phase of infection. p24 is a core protein found in the HIV virus. It is an essential structural component of the viral capsid, which surrounds and protects the viral genetic material.
The p24 protein is released into the bloodstream during the early stages of HIV infection. By targeting p24, the test can detect HIV infection at an earlier stage when viral loads are high, enabling timely interventions, treatment initiation, and prevention of further transmission.
This early detection plays a vital role in improving patient outcomes, reducing the spread of HIV, and facilitating effective public health strategies.
NeoVentures has developed aptamers specifically for targeting p24 for the purposes of creating a diagnostic test for HIV.
Surface Plasmon Resonance
Evaluation of the binding of our p24-specific aptamer to p24 (black) and HSA (red line) via Surface Plasmon Resonance (SPR).
This demonstrates robust binding of the target molecule to p24, indicated by a strong and specific signal. Importantly, there is no detectable binding to HSA, confirming the specificity of the interaction and ruling out any undesirable non-specific binding, which is essential for the accuracy and reliability of the assay.
Surface Plasmon Resonance
Evaluation of the binding of our p24-specific aptamer to p24 (black) and HSA (red line) via Surface Plasmon Resonance (SPR).
This demonstrates robust binding of the target molecule to p24, indicated by a strong and specific signal. Importantly, there is no detectable binding to HSA, confirming the specificity of the interaction and ruling out any undesirable non-specific binding, which is essential for the accuracy and reliability of the assay.
Lateral Flow
In the lateral flow image, the p24 aptamer demonstrates precise binding to the p24 protein on the lateral flow strips (top set of three strips), highlighted by a distinct signal.
Remarkably, no binding is observed to the off targets, G12v (a protein with a comparable size) or HSA (an abundant protein found in blood), underscoring the aptamer’s exceptional specificity, selectivity, and reproducibility for the p24 protein.
Lateral Flow
In the lateral flow image, the p24 aptamer demonstrates precise binding to the p24 protein on the lateral flow strips (top set of three strips), highlighted by a distinct signal.
Remarkably, no binding is observed to the off targets, G12v (a protein with a comparable size) or HSA (an abundant protein found in blood), underscoring the aptamer’s exceptional specificity, selectivity, and reproducibility for the p24 protein.
How Neomers Changes Aptamer Science
Neomers overcomes all the problems SELEX has.
Due to the novel way that the library is designed, we are able to start with the same library for every selection. This allows us to complete selection on our target, as well as any off targets separately.
Using this method, we are able to account for those sequences that bind to the off targets, even those that bind weakly, and remove them from the list of potential sequences to be chosen if they also appear in our target binding sequencing results. Since this is all from the same library, we are constantly learning what sequences bind to certain targets.
We have already characterized the binding of our Neomer library to Human Serum Albumin (HSA), IgG, and other proteins found in high abundance in blood. This allows us to create an ‘immune tolerance’ system in-silico and remove any sequences that bind to a ‘self’ antigen.
Neomers will enable more successful applications of aptamers.
How Neomers Changes Aptamer Science
Neomers overcomes all the problems SELEX has.
Due to the novel way that the library is designed, we are able to start with the same library for every selection. This allows us to complete selection on our target, as well as any off targets separately.
Using this method, we are able to account for those sequences that bind to the off targets, even those that bind weakly, and remove them from the list of potential sequences to be chosen if they also appear in our target binding sequencing results. Since this is all from the same library, we are constantly learning what sequences bind to certain targets.
We have already characterized the binding of our Neomer library to Human Serum Albumin (HSA), IgG, and other proteins found in high abundance in blood. This allows us to create an ‘immune tolerance’ system in-silico and remove any sequences that bind to a ‘self’ antigen.
Neomers will enable more successful applications of aptamers.
About NeoVentures
NeoVentures was founded in 2002 and has since become the world leader in aptamer development and applications. The company was co-founded by Ximena Vedoya and Gregory Penner based on their observation of the need to bridge the gap between aptamer discovery and commercial application.
We are committed to applying innovative approaches to improving health care. Our expertise and passion will help you unlock new market opportunities.
About NeoVentures
NeoVentures was founded in 2002 and has since become the world leader in aptamer development and applications. The company was co-founded by Ximena Vedoya and Gregory Penner based on their observation of the need to bridge the gap between aptamer discovery and commercial application.
We are committed to applying innovative approaches to improving health care. Our expertise and passion will help you unlock new market opportunities.
English 
French 
Spanish